Extensive-stage Small-cell Lung Cancer, Refractory Extensive Stage Small Cell Lung Carcinoma

Trial Radar AI Trial Candidate or Patient Patient Caregiver Healthcare Pro Biotech Pro Biotech Investor Researcher Other
	Showing clinical trials for Extensive-stage Small-cell Lung Cancer, Refractory Extensive Stage Small Cell Lung Carcinoma. I can help you find clinical trials in specific locations and provide insights on health conditions and treatments. With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

Showing clinical trials for Extensive-stage Small-cell Lung Cancer, Refractory Extensive Stage Small Cell Lung Carcinoma.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

Study Title	Status
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer NCT03672773	Active, not recruiting
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (MGC018-SCLC) NCT06227546	Active, not recruiting
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01) NCT05280470	Active, not recruiting
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer NCT04607954	Active, not recruiting
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC NCT06348797	Recruiting
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC NCT04010357	Active, not recruiting
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) NCT04938817	Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) NCT06780137	Recruiting
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) (DART-NK-SCLC) NCT07480213	Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer NCT07325136	Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers NCT05882058	Recruiting

Clinical Trial Radar

Phase

Type

Study Type

Age Group

Biological Sex

Placebo

Phase

Type

Study Type

Age Group

Biological Sex